AxoGen (AXGN) Leerink Global Healthcare Conference 2026 summary

Business evolution and strategic priorities

• Strategic planning and business model testing over the past two years have validated growth assumptions and demonstrated elasticity in the business.

• All business segments are growing at double-digit rates, with no single area dominating performance.

• Expansion into under-penetrated markets, especially breast, is a key driver, with only 200 of 1,200 potential sites established.

• Market development focuses on establishing nerve function restoration as a standard of care, addressing historically unmet needs.

• Execution rigor and scaling are emphasized as critical for sustained growth.

Financial position and guidance

• Recent capital raise netted $133 million, eliminating $68 million in debt and strengthening the balance sheet.

• Guidance for 2026 is at least 18% top-line growth, based on early-stage market penetration and basic sales cycle assumptions.

• No incremental payer wins are factored into 2026 guidance.

• Commercial momentum in late 2025 included over 20% top-line growth in Q3 and Q4.

Regulatory and operational milestones

• Achieved Biologics License Application (BLA) approval for AVANCE, affirming product status but not unlocking new patients.

• BLA enables operational efficiencies by consolidating quality systems and allows for capital investment to improve gross margins.

• BLA supports payer engagement, with formal submissions to reevaluate coverage now underway.

• New manufacturing and process improvements are expected to drive gross margin increases starting in 2027.